MetaCap

Opus Genetics (IRD) vs Oculis (OCS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Opus Genetics (IRD) has outperformed Oculis (OCS) over the past year, gaining 108.9% versus a loss of 63.3%. Over five years, IRD leads with a -8.3% price change compared with -27.3% for OCS. Oculis is the larger company by market cap ($393.4 million vs $385.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRD+108.90%OCS-63.34%
+232%+77%-79%
Nov 21, 20251 yearNov 20, 2026
IRD+9.62%OCS-27.66%
+250%+77%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRD versus OCS key metrics
MetricIRDOCS
Share price$3.99$7.06
Market cap$385.65M$393.35M
1-day change-2.21%-5.11%
YTD return+98.51%-64.65%
1-year return+108.90%-63.34%
5-year return-8.28%-27.29%
EPS (TTM)$-1.48$-1.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.20M—
Revenue growth (YoY)+29.15%—
Net income (latest FY)$-49.59M—
Operating margin-271.90%—
Net margin-349.33%—
52-week high$7.07$34.48
52-week low$1.88$6.78
Distance from 52-week high-43.56%-79.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+249.37%+407.79%
Average volume2.56M272.83K
Shares outstanding96.65M55.72M
Employees2760
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IRD has outperformed OCS by 172.2 percentage points over the past year.

About Opus Genetics

IRD stock →

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

About Oculis

OCS stock →

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

IRD vs OCS FAQ

Which is bigger, Opus Genetics or Oculis?

Oculis (OCS) is larger, with a market capitalization of $393.35M compared with $385.65M for Opus Genetics (IRD).

Which stock has performed better over the past year, IRD or OCS?

IRD returned +108.90% over the past 12 months, compared with -63.34% for OCS (price return, excluding dividends). Past performance does not predict future results.

Are Opus Genetics and Oculis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons